Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-intrinsic signatures of esophageal adenocarcinoma associate with cellular phenotypes and responses to therapy

ABSTRACT: We have discovered the existence of 2 subtypes of esophageal adenocarcinoma (EAC): an intestinal-like (epithelial) subtype and a mesenchymal-like subtype. We aimed to discover distinct drug vulnerabilities in these subtypes, and found that the intestinal subtype is more sensitive to RTK inhibition. By profiling the phosphoproteome of our cell line panel (of which 4 are intestinal-like and 4 mesenchymal-like), we aim to elucidate distinct signalling pathways in our subtypes to explain different drug vulnerabilities.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Thang Pham

LAB HEAD: Connie Jimenez

PROVIDER: PXD047796 | Pride | 2026-05-21

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MaxQuant-txt-IMAC.zip	Other
	MaxQuant-txt-expression.zip	Other
	MaxQuant-txt-pTyr.zip	Other
	TIM_1109_2023-09-13_S3-A1_OPL2052_S001_pY-IP_NoTx_Intestinal_Stem_Cell_031M_Repl1.d.tar	Other
	TIM_1110_2023-09-13_S3-A2_OPL2052_S002_pY-IP_NoTx_Intestinal_Primary_081R_Repl1.d.tar	Other

Items per page:

1 - 5 of 67

Similar Datasets

The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.

Project description:Ampullary adenocarcinoma (AAC) is a rare gastrointestinal cancer with varying survival rates, particularly the aggressive pancreatobiliary (PB) subtype. Adjuvant therapy benefits only PB and mixed subtype patients, while prospective studies are required for validation. A study proposes tailored adjuvant treatments (CAPOX for intestinal subtype, FOLFIRINOX for PB and mixed subtypes) based on histopathology to enhance survival, also exploring molecular sub-studies for deeper insights.

| 108044 | ecrin-mdr-crc

The proteome of bilateral macronodular adrenocortical disease (BMAD) shows different profiles correlating with the genetic causes and reveals specific dysregulation of RNA polymerase II and cholesterol biosynthesis enzymes.

Project description:Bilateral macronodular adrenocortical disease (BMAD) is currently described as composed of 4 microscopic subtypes (subtype 1 to 4) and 3 molecular groups (ARMC5-altered, KDM1A-altered, and unknown). Little is known about protein heterogeneity and its links with BMAD characteristics. The aim of this work is to study the protein signatures of BMAD and their correlations with microscopy and genetics. Liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed on 24 BMAD: 7 ARMC5, 4 KDM1A, 13 non-KDM1A, non-ARMC5 BMAD and 2 normal adrenal glands as control. Proteomic data were analyzed by principal component analysis followed by non-negative matrix factorization. Unsupervised clustering divided samples into 3 proteomic groups. The first group is composed of ARMC5-altered BMAD and is characterized by accumulation of RNA polymerase II (Pol II) subunits. The second comprises KDM1A-altered patients and subtype 4 BMAD. It is characterized by accumulation of cholesterol biosynthesis enzymes (such as FDFT1). The final group has no specific signature detected and is composed of subtypes 1 and 3 BMAD. Our study is the first to explore BMAD proteome using LC-MS/MS. The 3 proteomic groups mostly overlap the 4 microscopic and 3 molecular groups of BMAD. Accumulation of Pol II subunits induced by ARMC5 inactivation is probably plays a role in the pathogenesis of those BMAD. KDM1A-altered and subtype 4 BMAD showed an accumulation of proteins involved in lipid metabolism that could contribute to hypercortisolism. These results reveal specific protein patterns pointing to various cellular processes opening new perspective to understand BMAD pathophysiology.

2025-12-16 | PXD070500 | Pride

Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses

Project description:Introduction: Ampullary cancer is a relatively rare entity and usually treated by pancreatoduodenectomy followed by adjuvant therapy. The intestinal subtype is associated with markedly improved prognosis after resection. Only few cell lines are available for in vitro studies of ampullary cancer and they have not been collectively characterized. Methods: We characterized available ampullary cancer cell lines by subtype maker expression, epithelial-mesenchymal transition (EMT) features, growth and invasion, drug sensitivity and response to cancer-associated fibroblast conditioned medium (CAF-CM). Results: On the basis of EMT features, subtype marker expression, growth, invasion and drug sensitivity three types of cell lines could be distinguished: mesenchymal-like, pancreatobiliary-like and intestinal-like. In response to CAF-CM, enhanced growth, EMT induction as well as suppression of intestinal differentiation markers were observed, but in a heterogenous pattern. Also proteomic analysis of the CAF response distinguished intestinal-like from other cell lines. Discussion: Most of the available AMPAC cell lines seem to reflect a poorly differentiated pancreatobiliary or mesenchymal-like phenotype, consistent with their origin. We suggest that the best cell line model for intestinal-like AMPAC is the SNU869 cell line, while others seem to reflect aggressive AMPAC subtypes.

2016-03-14 | PXD002657 | Pride

Proteomic characterization of the effect of CBD in animal models of PWA

Project description:The effect of CBD was investigated in a preclinical model of PCOS generated by chronic exposure of female mice to DHT from weaning onwards. To exacerbate the metabolic complications in this model, PWA mice were fed a high-fat diet (HFD) for 18 weeks before initiation of the pharmacological treatments. This model phenocopies a subtype of women with this condition who suffer metabolic comorbidities. PWA exacerbated the metabolic disturbances induced by the high-fat diet (HFD), as HFD-fed, non-androgenized female mice exhibited a smaller increase in body weight (BW) compared to androgenized females on the same diet before treatment initiation (Fig. 1A). Daily treatment with CBD for 28 days caused a clear reduction of BW through the treatment period. This datset contains the results of a proteomic characterization of the livers from control mice, PWA mice and CBD treated mice.

2025-08-05 | PXD061045 | Pride

Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: H358 Drug Response Phosphoproteomics

Project description:Covalent inhibitors of KRASG12C (KRASi) hold considerable progress for tumors driven by this oncogene yet early studies suggest rapid mechanisms of adaptive resistance that appear cell type dependent. To address these challenges, we performed mass spsectrometry baesd phosphoproteomics analysis in KRASG12C cell lines after short term treatment with ARS-1620 and compared phosphoproteomes of KRASG12C cells to understand signaling diversity. Our analysis suggests individual KRASG12C cells responds uniquely to perturbation of KRASG12C. Cell line models can be categorized in epithelial or mesenchymal subtypes and a similar pattern was observed in KRASG12C human lung cancer tumor tissues. ERBB2/3 signaling compensate for repressed ERK signaling following ARS-1620 treatment in epithelial cell type, and this subtype was also more responsive to inhibition of SHP2, IGFR, and SOS1. Conversely, FGFR signaling drives resistance to KRASi in mesenchymal cells in part via mTOR signaling. These studies suggest transcriptional subtypes of KRASG12C dictate responsiveness to specific combinations.

2021-02-15 | PXD021611 | Pride

Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: Calu-1 Drug Response Phosphoproteomics

Project description:therapy, drug resistance, signal transduction Covalent inhibitors of KRASG12C (KRASi) hold considerable progress for tumors driven by this oncogene yet early studies suggest rapid mechanisms of adaptive resistance that appear cell type dependent. To address these challenges, we performed mass spsectrometry baesd phosphoproteomics analysis in KRASG12C cell lines after short term treatment with ARS-1620 and compared phosphoproteomes of KRASG12C cells to understand signaling diversity. Our analysis suggests individual KRASG12C cells responds uniquely to perturbation of KRASG12C. Cell line models can be categorized in epithelial or mesenchymal subtypes and a similar pattern was observed in KRASG12C human lung cancer tumor tissues. ERBB2/3 signaling compensate for repressed ERK signaling following ARS-1620 treatment in epithelial cell type, and this subtype was also more responsive to inhibition of SHP2, IGFR, and SOS1. Conversely, FGFR signaling drives resistance to KRASi in mesenchymal cells in part via mTOR signaling. These studies suggest transcriptional subtypes of KRASG12C dictate responsiveness to specific combinations.

2021-02-15 | PXD021608 | Pride

Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: Protein Expression

2021-02-15 | PXD021603 | Pride

Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: Drug Response pY Profiling

2021-02-15 | PXD021607 | Pride

Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: Tyrosine Phosphorylation

2021-02-15 | PXD021604 | Pride

Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: H1792 Drug Response Phosphoproteomics

2021-02-15 | PXD021609 | Pride